Literature DB >> 10328583

Molecular and cellular effects of methotrexate.

M Seitz1.   

Abstract

In 1998, knowledge about the mechanisms of action of methotrexate (MTX) in immunoinflammatory disorders further increased. The most interesting results to date came from studies showing that most of the anti-inflammatory actions of MTX are mediated by adenosine, which may account for the profound effects of MTX on cytokines, cytokine inhibitors, and cell differentiation. Finally, potential novel pharmacologic strategies are discussed based on actual knowledge about the molecular and cellular actions of MTX.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328583     DOI: 10.1097/00002281-199905000-00012

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  21 in total

Review 1.  [The treatment of juvenile rheumatism: pharmacotherapy].

Authors:  F Weller; H-I Huppertz
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 2.  Treating difficult crystal pyrophosphate dihydrate deposition disease.

Authors:  Nadia Announ; Pierre-André Guerne
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 3.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 4.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

5.  A role for methotrexate in the management of non-infectious orbital inflammatory disease.

Authors:  J R Smith; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

6.  Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation.

Authors:  David L Delano; M Carmen Montesinos; Avani Desai; Tuere Wilder; Patricia Fernandez; Peter D'Eustachio; Tim Wiltshire; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2005-08

7.  Management of orbital xanthogranuloma with methotrexate.

Authors:  Ashley Hayden; David J Wilson; James T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2006-11-29       Impact factor: 4.638

8.  Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis.

Authors:  Amita Aggarwal; Ramnath Misra
Journal:  Rheumatol Int       Date:  2003-03-07       Impact factor: 2.631

9.  [Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs].

Authors:  C Fiehn; G Keyßer; H-M Lorenz
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

Review 10.  A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.

Authors:  Kamran Ghoreschi; Ulrich Mrowietz; Martin Röcken
Journal:  J Mol Med (Berl)       Date:  2003-07-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.